US
CA
NZ
UK
AU
IND
Last update at 2025-05-20T17:08:23.049159Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Veraxa and OmniAb to develop bispecific ADC tumour programme
Tue 06 May 25, 02:09 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -26.06100M | -34.35000M | -23.72800M | -13.02700M |
| Minority interest | - | - | - | - |
| Net income | -22.33400M | -27.04200M | -17.55700M | -13.58900M |
| Selling general administrative | 24.90M | 16.95M | 10.22M | 8.65M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 59.08M | 34.75M | 23.27M | 18.32M |
| Reconciled depreciation | 13.05M | 16.25M | 13.14M | 10.92M |
| Ebit | -26.64800M | -35.60900M | -25.62300M | -13.02700M |
| Ebitda | -13.01100M | -18.09100M | -10.58600M | -2.11000M |
| Depreciation and amortization | 13.64M | 17.52M | 15.04M | 10.92M |
| Non operating income net other | - | - | - | - |
| Operating income | -26.64800M | -35.60900M | -25.62300M | -13.02700M |
| Other operating expenses | 85.72M | 70.36M | 48.89M | 31.34M |
| Interest expense | 0.59M | 0.00700M | 0.00500M | 0.00000M |
| Tax provision | -3.72700M | -7.30800M | -6.17100M | 0.56M |
| Interest income | 0.59M | - | - | - |
| Net interest income | 0.59M | -0.00700M | -0.00500M | 0.00000M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | -3.72700M | -7.30800M | -6.17100M | 0.56M |
| Total revenue | 59.08M | 34.75M | 23.27M | 18.32M |
| Total operating expenses | 85.72M | 70.36M | 48.89M | 31.34M |
| Cost of revenue | - | - | - | - |
| Total other income expense net | 0.59M | 1.26M | 1.90M | - |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -22.33400M | -27.04200M | -17.55700M | -13.58900M |
| Net income applicable to common shares | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 325.56M | 401.99M | 421.21M | 304.46M | 295.38M |
| Intangible assets | 138.06M | 155.47M | 167.24M | 176.32M | 186.64M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.43M | 4.07M | 6.39M | 1.41M | 0.77M |
| Total liab | 37.94M | 87.40M | 79.84M | 70.16M | 59.84M |
| Total stockholder equity | 287.62M | 314.58M | 341.37M | 234.31M | 235.54M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 6.67M | 8.37M | 13.06M | 6.28M | 6.07M |
| Common stock | 0.01M | 0.01M | 0.01M | - | - |
| Capital stock | 0.01M | 0.01M | 0.01M | - | - |
| Retained earnings | -101.40000M | -39.36700M | 11.25M | - | - |
| Other liab | - | - | - | - | - |
| Good will | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M |
| Other assets | - | - | - | - | - |
| Cash | 27.60M | 16.36M | 33.39M | -13.85100M | -2.59200M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15.09M | 23.12M | 26.02M | 20.58M | 14.28M |
| Current deferred revenue | 2.34M | 6.85M | 8.21M | 10.79M | 7.16M |
| Net debt | -4.43400M | 9.20M | -7.59400M | 27.70M | 5.18M |
| Short term debt | 3.78M | 3.49M | 1.78M | 0.58M | 0.58M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 23.16M | 25.56M | 25.80M | 13.85M | 2.59M |
| Other stockholder equity | 388.98M | 353.89M | 330.10M | - | - |
| Property plant equipment | - | - | - | - | - |
| Total current assets | 68.14M | 94.90M | 124.95M | 22.54M | 16.65M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | - |
| Short term investments | 31.84M | 70.62M | 54.88M | - | - |
| Net receivables | 5.27M | 3.84M | 30.29M | 21.14M | 15.88M |
| Long term debt | - | - | - | - | - |
| Inventory | - | 0.00000M | - | 13.85M | 2.59M |
| Accounts payable | 2.30M | 4.41M | 2.97M | 2.92M | 0.47M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.03M | 0.05M | 0.00900M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.10M | 2.19M | -17.76200M | 1.50M | 2.13M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 257.42M | 307.08M | 296.26M | 281.92M | 278.73M |
| Capital lease obligations | 23.16M | 25.56M | 25.80M | 13.85M | 2.59M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -73.31300M | -4.02500M | -26.98000M | -12.09500M |
| Change to liabilities | - | - | - | - |
| Total cashflows from investing activities | - | - | - | - |
| Net borrowings | - | - | - | - |
| Total cash from financing activities | 110.74M | 9.70M | 23.36M | 17.29M |
| Change to operating activities | - | - | - | - |
| Net income | -22.33400M | -27.04200M | -17.55700M | -13.58900M |
| Change in cash | 33.84M | 0.00000M | 0.00000M | 0.00000M |
| Begin period cash flow | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| End period cash flow | 33.84M | 0.00000M | 0.00000M | 0.00000M |
| Total cash from operating activities | -3.58700M | -5.67200M | 3.62M | -5.19500M |
| Issuance of capital stock | 96.68M | - | - | - |
| Depreciation | 18.25M | 16.25M | 13.14M | 10.92M |
| Other cashflows from investing activities | - | - | - | - |
| Dividends paid | - | - | - | - |
| Change to inventory | - | - | - | - |
| Change to account receivables | -12.73700M | 6.02M | 0.34M | -4.29000M |
| Sale purchase of stock | - | - | - | - |
| Other cashflows from financing activities | 14.06M | 9.70M | 23.36M | 17.29M |
| Change to netincome | - | - | - | - |
| Capital expenditures | 17.17M | 4.07M | 1.75M | 0.26M |
| Change receivables | - | - | - | - |
| Cash flows other operating | - | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - |
| Change in working capital | -10.83300M | -2.63100M | 4.73M | -8.92200M |
| Stock based compensation | 18.32M | 15.06M | 9.16M | 6.66M |
| Other non cash items | -0.57200M | 0.00900M | 0.33M | -0.81800M |
| Free cash flow | -20.75500M | -9.74200M | 1.87M | -5.45000M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| OABIW OmniAb Inc. |
- -% | - | - | - | - | - | ||
| NVO Novo Nordisk A/S |
1.23 1.83% | 68.25 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.60 5.42% | 70.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.40 0.77% | 444.06 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
10.20 1.71% | 606.74 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
5980 Horton Street, Emeryville, CA, United States, 94608
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew W. Foehr | Pres, CEO & Director | 1973 |
| Mr. Kurt A. Gustafson | Exec. VP of Fin. & CFO | 1968 |
| Marie-Cecile Van De Lavoir D.V.M., Ph.D. | VP of Operations | NA |
| Mr. Charles S. Berkman J.D. | Chief Legal Officer & Sec. | 1969 |
| Bill Harriman Ph.D. | SVP of Antibody Discovery | NA |
| Mr. Matthew W. Foehr | President, CEO & Director | 1973 |
| Mr. Kurt A. Gustafson | Executive VP of Finance & CFO | 1968 |
| Mr. Charles S. Berkman J.D. | Chief Legal Officer & Secretary | 1969 |
| Ms. Cia McCaffrey | Vice President of People & Talent | NA |
| Dr. Bill Harriman Ph.D. | Senior Vice President of Antibody Discovery | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...